Trial Profile
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2013
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Heparin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms ASPIRE-Pilot
- Sponsors Organon; Schering-Plough
- 10 Dec 2013 Status changed from completed to unconfirmed.
- 05 Dec 2005 New trial record.